CYSTINOSIS RESEARCH FOUNDATION
AND SUBSIDIARY

CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2017

WITH INDEPENDENT AUDITORS' REPORT THEREON
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organizational Data</td>
<td>i</td>
</tr>
<tr>
<td>Independent Auditors' Report</td>
<td>1</td>
</tr>
<tr>
<td>Consolidated Statement of Financial Position</td>
<td>4</td>
</tr>
<tr>
<td>Consolidated Statement of Activities</td>
<td>5</td>
</tr>
<tr>
<td>Consolidated Statement of Functional Expenses</td>
<td>6</td>
</tr>
<tr>
<td>Consolidated Statement of Cash Flows</td>
<td>7</td>
</tr>
<tr>
<td>Notes to Consolidated Financial Statements</td>
<td>8</td>
</tr>
</tbody>
</table>
ORGANIZATIONAL DATA
NATALIE’S WISH

Natalie’s wish, ‘To have my disease go away forever’ – those seven words provided the inspiration to establish the Cystinosis Research Foundation (CRF) in 2003. We knew at that moment that we needed to make every effort to make Natalie’s wish – and the wish of others with cystinosis – a reality.

MISSION STATEMENT

CRF’s mission is to support bench, clinical and translational research to find better treatments and a cure for cystinosis.

RESEARCH

CRF is dedicated to finding better treatments to improve the quality of life for those with cystinosis and to ultimately find a cure for this devastating disease.

CRF has an aggressive research agenda. CRF issues grants for bench and clinical research studies bi-annually in an effort to accelerate the research process and ensure that cystinosis research is on-going and focused on novel treatments and a cure.

HISTORY AND RESEARCH

Cystinosis is a rare, metabolic and genetic disease that afflicts approximately 2,000 children and adults worldwide. CRF’s focus is increasingly on the clinical and translational research crucial to making strides towards a cure for cystinosis. CRF is committed to prioritizing and aggressively supporting research which has the potential to significantly improve the quality of life for patients with cystinosis.

CRF announces two global calls for research proposals each year. After careful evaluation of every application by the CRF Scientific Review Board, research grants are awarded. In 2006, CRF established the first Cystinosis Research Fellowship Program designed to support scientists and new researchers who have an interest in cystinosis.

RESEARCH GIVES US HOPE

We firmly believe that research gives us HOPE – and hope allows us to live with cystinosis until the day a cure is found.
Since 2003, the Cystinosis Research Foundation (CRF) has become the largest fund provider of cystinosis research in the world – raising more than $39 million. CRF has changed the course of cystinosis by investing donors’ gifts strategically and aggressively to create a thriving research community. From the beginning, all CRF operating costs are privately underwritten so that 100 percent of the funds donated goes to support cystinosis research.

We are pleased to announce that in the spring 2017 Call for Research Proposals, CRF awarded eight new grants totaling more than $1.55 million for cystinosis research. The new grants bring us that much closer to better treatments and a cure.

CRF has issued grants to the best and brightest researchers in the world. To date, we have funded 159 multi-year research studies at leading research institutions in 12 countries. CRF-funded researchers have published more than 67 articles in prestigious, top-rated journals. Those articles, available to everyone in the world, have added to the understanding of the pathogenesis of cystinosis.

From the beginning, we have understood that funding basic and bench research was important to understanding cystinosis. Over the years, as discoveries were made in the lab, CRF began funding clinical research, and now we are translating the data from the clinical studies to the patients. One of our earliest milestones, and the one of which we are most proud, is that CRF funded every bench and clinical trial that led to the discovery of a delayed-release form of the life-saving medication cystinosis patients must take. The delayed-release medication, approved by the FDA in 2013, is considered the most significant advancement in the treatment of cystinosis in 30 years. Our latest research milestone is the creation of the first donor stem cell transplantation trial at UCLA, which brings us tantalizingly close to a cure.

Moving forward, we have targeted several areas of research including muscle wasting, neurological issues, corneal cystinosis, and stem cell and gene therapy, all with the goal of finding better treatments and a cure for cystinosis.

NANOTECHNOLOGY AND CORNEAL CYSTINOSIS

We are dedicated to finding better treatments for corneal cystinosis. Corneal cystinosis is the build-up of cystine crystals in the eyes that causes photophobia (extreme sensitivity to light) severe eye pain, and sometimes, blindness. There is an existing treatment but it is rigorous and requires hourly dosing of medicated eye drops. For many, compliance is difficult.

Ghanashyam Acharya, PhD, and Jennifer Simpson, MD, have collaborated on a novel treatment for corneal cystinosis. Dr. Acharya has invented a nanowafer that we believe will revolutionize the treatment of corneal cystinosis. The nanowafer can be loaded with cysteamine medication to treat corneal cystinosis. The nanowafer is placed in the eye, and as it dissolves, the medication slowly releases in the eye offering relief for hours.

In 2016, CRF formed Corneal Cystinolysis, Inc., (CCI) for the purpose of research and development of a novel treatment for corneal cystinosis. The treatment proposes to use a nanowafer loaded with cysteamine medication to treat corneal cystinosis. CRF owns the license for the cysteamine nanowafer which ensures that we remain focused and committed to bringing the new treatment to the patients. The scientist who developed the nanowafer is Dr. Ghanshyam Acharya at Baylor College of Medicine. CRF and Dr. Acharya are committed to this project and hope to file a new drug application in 2018.
STEM CELL AND GENE THERAPY

We believe that stem cells will be the cure for cystinosis. CRF works closely with Stéphanie Cherqui, PhD, whose focus is stem cells and gene therapy. Dr. Cherqui has worked together with the FDA for several years and is awaiting FDA approval to commence the first autologous stem cell and gene therapy clinical trial. We are optimistic that the FDA will approve this study in 2017. Once it is approved, we can help recruit patients soon thereafter. Dr. Cherqui’s work is our hope; not only has the treatment reversed cystinosis in mice, last year she successfully cured corneal cystinosis in the mouse model.

CYSTINOSIS RESEARCH HELPS OTHERS

Many of the discoveries made by CRF researchers are currently being applied to other more prevalent and well-known disorders and diseases including other corneal diseases, kidney diseases and genetic and systemic diseases similar to cystinosis. Support for cystinosis research has reached far beyond the cystinosis community. A cure for cystinosis will help find cures for other diseases potentially helping millions of people.

CRF FAMILIES AND PARTNERS

The Cystinosis Research Foundation has witnessed tremendous growth as other cystinosis families have joined our efforts. Their friends and families have embraced the cystinosis cause and enthusiastically raise funds to support cystinosis research through CRF. We have found strength in numbers and our joint effort gives us a renewed sense of community and purpose.

DAY OF HOPE CONFERENCE

Each year the Cystinosis Research Foundation hosts the Day of Hope Family Conference. In 2016, 56 families from around the world gathered along with CRF funded researchers to share stories, hopes and dreams and build life-long friendships. Leading cystinosis researchers shared their progress on gene and stem cell therapies, novel eye research and neurological challenges related to cystinosis. The conference allows families to learn more about the ongoing cystinosis research and the hope it brings to our community.

CURE CYSTINOSIS INTERNATIONAL REGISTRY

The Cure Cystinosis International Registry (CCIR) was launched in 2010 and now has approximately 576 cystinosis patients registered from 44 countries. The Cystinosis Research Foundation in partnership and collaboration with the Cystinosis Foundation and twelve other cystinosis family foundations from around the world, established this comprehensive, global patient registry for cystinosis. The CCIR questionnaire was developed by medical and scientific experts specifically for the cystinosis community. To improve accessibility, the CCIR has been translated into Spanish, Portuguese, Dutch and French. It is our mission to register every person with cystinosis, thus connecting them to the research community in an effort to find a cure for cystinosis. The CCIR is a central hub of information and is an essential tool for the global cystinosis research community. We are certain that the information provided by the patients will accelerate the research process and unite us in our quest to find a cure for cystinosis.
CRF INTERNATIONAL RESEARCH SYMPOSIUM

CRF’s International Research Symposium is held every two years and is only open to invited researchers and scientists. Approximately 65 cystinosis experts from leading international universities and research institutions gather to share their research data and to discuss cutting edge research ideas in an effort to accelerate research. The symposium is known for the openness of the attendees, and for their willingness to work together and form collaborations. The symposium has created a synergistic research community working in partnership with CRF.
INDEPENDENT AUDITORS’ REPORT

The Board of Directors
Cystinosis Research Foundation and Subsidiary
Irvine, California

We have audited the accompanying consolidated financial statements of Cystinosis Research Foundation and Subsidiary (a nonprofit organization) (the “Foundation”) which comprise the consolidated statement of financial position as of June 30, 2017, and the related consolidated statements of activities, functional expenses, and cash flows for the six-month period ended June 30, 2017, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
The Board of Directors  
Cystinosis Research Foundation and Subsidiary  

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.  

Opinion  

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Cystinosis Research Foundation and Subsidiary as of June 30, 2017, and the changes in their net assets and their cash flows for the six-month period ended June 30, 2017 in accordance with accounting principles generally accepted in the United States of America.  

Redwitz, Inc.  

Redwitz, Inc.  
Irvine, California  
October 26, 2017
FINANCIAL STATEMENTS
CYSTINOSIS RESEARCH FOUNDATION AND SUBSIDIARY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
JUNE 30, 2017

Assets:
Current Assets:
   Cash and cash equivalents $ 5,569,068
   Receivables:
      Pledges 877,583
      Grant 100,000
      Other 13,916
   Investments 1,527,861
   Prepaid expenses 68,996
Total Assets $ 8,157,424

Liabilities:
Current Liabilities:
   Accounts payable $ 38,653
   Grants payable - current portion 1,319,477
   Accrued expenses 3,369
   Total current liabilities 1,361,499
   Long-Term Liability - Grants Payable, net of Current Portion 361,250
   Total liabilities 1,722,749
Net Assets - Unrestricted 6,434,675
Total Liabilities and Net Assets $ 8,157,424

See accompanying notes.
## CYSTINOSIS RESEARCH FOUNDATION AND SUBSIDIARY
### CONSOLIDATED STATEMENT OF ACTIVITIES
### FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unrestricted:</strong></td>
<td></td>
</tr>
<tr>
<td>Revenues and Other Support:</td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 1,091,654</td>
</tr>
<tr>
<td>Fundraising, net of direct benefits to donors</td>
<td>3,004,235</td>
</tr>
<tr>
<td>Interest</td>
<td>6,422</td>
</tr>
<tr>
<td>Investment returns - net gain</td>
<td>81,345</td>
</tr>
<tr>
<td><strong>Total revenues and other support</strong></td>
<td>4,183,656</td>
</tr>
<tr>
<td>Expenses:</td>
<td></td>
</tr>
<tr>
<td>Program services:</td>
<td></td>
</tr>
<tr>
<td>Research and education</td>
<td>1,453,597</td>
</tr>
<tr>
<td>Nanowafer research and development</td>
<td>292,829</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>1,746,426</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
</tr>
<tr>
<td>General and administrative</td>
<td>125,783</td>
</tr>
<tr>
<td>Fundraising</td>
<td>399,192</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>524,975</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>2,271,401</td>
</tr>
<tr>
<td>Increase in Unrestricted Net Assets</td>
<td>1,912,255</td>
</tr>
<tr>
<td><strong>Unrestricted Net Assets, Beginning of Period</strong></td>
<td>4,522,420</td>
</tr>
<tr>
<td><strong>Unrestricted Net Assets, End of Period</strong></td>
<td>$ 6,434,675</td>
</tr>
</tbody>
</table>

See accompanying notes.
# Cystinosis Research Foundation and Subsidiary
## Consolidated Statement of Functional Expenses
### For the Six-Month Period Ended June 30, 2017

<table>
<thead>
<tr>
<th></th>
<th>Program Services</th>
<th>General and Administrative</th>
<th>Fundraising</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounting</td>
<td>$</td>
<td>$ 11,806</td>
<td>$ 4,873</td>
<td>$ 16,679</td>
</tr>
<tr>
<td>Advertising/Public relations</td>
<td>3,070</td>
<td>-</td>
<td>111,794</td>
<td>114,864</td>
</tr>
<tr>
<td>Auction items</td>
<td>-</td>
<td>-</td>
<td>2,874</td>
<td>2,874</td>
</tr>
<tr>
<td>Credit card fees</td>
<td>-</td>
<td>-</td>
<td>18,905</td>
<td>18,905</td>
</tr>
<tr>
<td>Education</td>
<td>232,086</td>
<td>-</td>
<td>-</td>
<td>232,086</td>
</tr>
<tr>
<td>Grants</td>
<td>1,149,350</td>
<td>-</td>
<td>-</td>
<td>1,149,350</td>
</tr>
<tr>
<td>Insurance</td>
<td>-</td>
<td>3,595</td>
<td>-</td>
<td>3,595</td>
</tr>
<tr>
<td>Magazine</td>
<td>21,528</td>
<td>-</td>
<td>41,500</td>
<td>63,028</td>
</tr>
<tr>
<td>Other</td>
<td>3,631</td>
<td>1,685</td>
<td>-</td>
<td>5,316</td>
</tr>
<tr>
<td>Outside services</td>
<td>11,250</td>
<td>39,177</td>
<td>48,373</td>
<td>98,800</td>
</tr>
<tr>
<td>Patient registry</td>
<td>4,500</td>
<td>-</td>
<td>-</td>
<td>4,500</td>
</tr>
<tr>
<td>Photography</td>
<td>-</td>
<td>-</td>
<td>55,749</td>
<td>55,749</td>
</tr>
<tr>
<td>Postage</td>
<td>-</td>
<td>8,875</td>
<td>703</td>
<td>9,578</td>
</tr>
<tr>
<td>Printing</td>
<td>25,551</td>
<td>2,556</td>
<td>23,516</td>
<td>51,623</td>
</tr>
<tr>
<td>Salaries</td>
<td>1,413</td>
<td>1,413</td>
<td>25,431</td>
<td>28,257</td>
</tr>
<tr>
<td>Supplies</td>
<td>-</td>
<td>1,359</td>
<td>34,056</td>
<td>35,415</td>
</tr>
<tr>
<td>Symposium</td>
<td>1,100</td>
<td>-</td>
<td>-</td>
<td>1,100</td>
</tr>
<tr>
<td>Taxes - payroll</td>
<td>118</td>
<td>118</td>
<td>2,134</td>
<td>2,370</td>
</tr>
<tr>
<td>Telephone</td>
<td>-</td>
<td>1,452</td>
<td>-</td>
<td>1,452</td>
</tr>
<tr>
<td>Tournament site</td>
<td>-</td>
<td>-</td>
<td>16,118</td>
<td>16,118</td>
</tr>
<tr>
<td>Travel</td>
<td>-</td>
<td>5,027</td>
<td>12,885</td>
<td>17,912</td>
</tr>
<tr>
<td>Website and software</td>
<td>-</td>
<td>39,916</td>
<td>281</td>
<td>40,197</td>
</tr>
<tr>
<td><strong>Total expenses before</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corneal Cystinolysis, Inc.</td>
<td>1,453,597</td>
<td>116,979</td>
<td>399,192</td>
<td>1,969,768</td>
</tr>
<tr>
<td>Corneal Cystinolysis, Inc.: Nanowafer research and development</td>
<td>292,829</td>
<td>-</td>
<td>-</td>
<td>292,829</td>
</tr>
<tr>
<td>Professional fees</td>
<td>-</td>
<td>3,157</td>
<td>-</td>
<td>3,157</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>5,647</td>
<td>-</td>
<td>5,647</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$ 1,746,426</strong></td>
<td><strong>$ 125,783</strong></td>
<td><strong>$ 399,192</strong></td>
<td><strong>$ 2,271,401</strong></td>
</tr>
</tbody>
</table>

See accompanying notes.

Page 6
Cash Flows from Operating Activities:
  Increase in net assets $1,912,255

Adjustments to reconcile increase in net assets
to net cash provided by operating activities:
  Realized gains on sales of investments $ (24,358)
  Unrealized gain on investments $ (45,695)

Changes in assets and liabilities:
  (Increases) decreases in:
    Receivables $ (927,753)
    Prepaid expenses $ 53,511
  Increases (decreases) in:
    Accounts payable $ (21,309)
    Accrued expenses $ (430)
    Grants payable $ (58,275)

  Total adjustments $ (1,024,309)

Net cash provided by operating activities $887,946

Cash Flows from Investing Activities:
  Purchases of investments $ (280,432)
  Proceeds from sales of investments $ 289,269

  Net cash provided by investing activities $8,837

Net Increase in Cash and Cash Equivalents $896,783

Cash and Cash Equivalents, Beginning of Period $4,672,285

Cash and Cash Equivalents, End of Period $5,569,068

Supplemental Disclosure of Cash Flow Information:
  Cash paid during the year for:
    Interest $-
    Income taxes $1,624

See accompanying notes.
1. ORGANIZATION AND NATURE OF SERVICES

The Cystinosis Research Foundation (“CRF”) was founded in 2003 as a California nonprofit public benefit corporation. The mission of CRF is two-fold and focused: to support bench, clinical and translational cystinosis research for better treatments and to find a cure for cystinosis. CRF is also dedicated to educating the public and the medical community about cystinosis to ensure early diagnosis and proper treatment. CRF’s support comes entirely from donor contributions.

In 2016, CRF established Corneal Cystinolysis, Inc. (“CCI”) as a Texas corporation. The business plan of CCI is to improve treatment for corneal cystinosis. This subsidiary is 100% owned by CRF.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The consolidated financial statements include the accounts of CRF and CCI. Collectively, these entities are referred to as the “Foundation”. All intercompany balances and transactions have been eliminated in the consolidation. The total assets of CCI were approximately $8,500 at June 30, 2017. No revenue was reported for the six-month period ended June 30, 2017. The net loss of CCI was approximately $301,600 for the six-month period ended June 30, 2017.

Basis of Accounting

The financial statements of the Foundation have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Financial Statement Presentation

The Foundation reports information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets and permanently restricted net assets.

Unrestricted Net Assets – Net assets that are not subject to donor-imposed restrictions. Unrestricted net assets generally result from unrestricted contributions and interest and dividends, less expenses incurred in providing services and fundraising and other administrative expenses.

Temporarily Restricted Net Assets – Net assets that are subject to donor-imposed restrictions that require the passage of time or the occurrence of a specific event to become available for unrestricted use. At June 30, 2017, there were no temporarily restricted net assets.
2. **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

**Financial Statement Presentation** (Continued)

*Permanently Restricted Net Assets* – Net assets that are subject to donor-imposed restrictions that may be maintained permanently while permitting the Foundation to use or expense part or all of the income derived from the donated assets. At June 30, 2017, there were no permanently restricted net assets.

**Use of Estimates and Assumptions**

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.

Significant estimates made in the accompanying financial statements include, but are not limited to, the valuation of investments. Actual results could differ from those estimates in the near term.

**Cash and Cash Equivalents**

For purposes of the statement of cash flows, the Foundation considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

**Concentration of Credit Risk**

The Foundation maintains deposits in excess of federally insured limits. This concentration in credit risk is managed by maintaining all deposits in high quality financial institutions.

**Risks and Uncertainties**

The Foundation invests in a combination of equity, fixed income, and other investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in risks in the near term could materially affect investments’ account balances and the amounts reported in the Statements of Activities and the Statements of Financial Position.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Pledges Receivable

Pledges receivable are unconditional promises to give towards the Foundation’s programs and are recorded as revenue when the pledge is received. At June 30, 2017, the Foundation considered all remaining pledges of $877,583, to be fully collectible. Accordingly, there were no allowances for doubtful pledges.

Investments and Fair Value Measurements

The carrying value of the Foundation’s cash and cash equivalents, pledges receivable, grant receivable, other receivables, prepaid expenses, accounts payable, and accrued expenses approximate their respective fair values due to their short maturities. Grants payable are discounted based upon the average yield of United States treasury securities with a two-year maturity which approximates fair value.

The Foundation reports investments in equity securities with readily determinable fair values and all investments in debt securities at quoted market values. The gains and losses are included in the Consolidated Statements of Activities. The Hedge Funds were valued based upon the internal financial statements of the various Portfolio Funds within the Hedge Fund or from redemption values at June 30, 2017. Such financial statements generally value securities and other financial instruments on a mark-to-market basis of accounting. The limited partnerships invest in hedge funds and private equity funds.

Property and Intangible Asset

Assets are carried at cost, if purchased, or fair market value at date of contribution, if contributed. Donations are reported as unrestricted support unless the donor has restricted the donated asset to a specific purpose. The Foundation follows the practice of capitalizing all expenditures for property in excess of $500. The Foundation’s website is an intangible asset subject to amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of five to seven years for software and the website. Property and intangible asset of $53,838 were fully depreciated at December 31, 2016.

Contributions and Grant Payments

Contributions received are recorded as unrestricted, temporarily restricted or permanently restricted net assets depending on the existence or nature of any donor restrictions.
2. **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

**Contributions and Grant Payments** (Continued)

Contributions made, including grant payments, can be either unconditional or conditional. Unconditional grants are recognized as an expense in the period in which they are approved. Grants, which are conditional upon a future and uncertain event, are expensed when these conditions are substantially met or expected to be met in a subsequent year. A conditional promise to give is considered unconditional if the possibility that the condition will not be met is remote.

Grants payable represents all unconditional grants that have been authorized prior to year end, but remain unpaid as of the statement of financial position date. There were no conditional grants at June 30, 2017.

**Functional Allocation of Expenses**

The costs of providing the various programs and other activities have been summarized on a functional basis in the Statements of Activities and in the Statements of Functional Expenses. CRF achieves some of its programmatic goals with its magazine. The joint costs associated with the magazine have been allocated to program services and to fundraising. Certain other costs have also been allocated among the programs and supporting services benefited.

The major programs of the Foundation are as follows:

- **Research** – CRF is dedicated to finding better treatments to improve the quality of life for those with cystinosis and to ultimately find a cure for this devastating disease. Through their aggressively funded research agenda, CRF issues grants for bench and clinical research studies bi-annually in order to accelerate research progress and ensure that cystinosis research is on-going and focused on novel treatments and a cure.

- **Education** – CRF is dedicated to educating the public and the medical community about cystinosis to ensure early diagnosis and proper treatment.

- **Corneal cystinosis nanowafer research and development** – CCI owns the license to the cysteamine nanowafer technology which research has shown will improve treatment for corneal cystinosis.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Income Taxes

CRF is a California nonprofit corporation which has qualified for tax exempt status under Section 501(c)(3) of the Internal Revenue Code and the State Revenue and Tax Code Section 23701(d). Accordingly, no provision of income taxes has been made in the accompanying financial statements.

CCI is treated as a C-Corporation for purposes of filing its federal and state income tax returns. Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due or refundable plus deferred taxes. CCI accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their perspective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled.

The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded, when necessary, to reduce deferred tax assets to the amount expected to be realized.

The Foundation follows the accounting for uncertainty in income taxes recognized in a nonpublic entity’s financial statements, including changes to CRF’s status as a not-for-profit entity. It details how entities should recognize, measure, present, and disclose uncertain tax positions that have been or are expected to be taken. As such, financial statements will reflect expected future tax consequences of uncertain tax positions presuming the taxing authorities’ full knowledge of the position and all relevant facts. Management believes that there was no impact to the Foundation’s financial statements as a result of these provisions.

Potential interest and penalties accrued related to unrecognized tax benefits are recorded within income tax expense. For the six-month period ended June 30, 2017, no interest or penalties were recorded in the Consolidated Statement of Activities. No interest or penalties were accrued in the Consolidated Statement of Position at June 30, 2017 relating to unrecognized benefits.

Advertising

The Foundation follows the policy of charging the costs of advertising to expenses as incurred. Advertising expense for the six-month period ended June 30, 2017 was approximately $115,000. For the six-month period ended June 30, 2017 approximately $20,400 of advertising expense was in-kind donations.
2. **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** (Continued)

**Subsequent Events**

The Foundation has evaluated subsequent events through October 26, 2017, the date the consolidated financial statements were available to be issued.

3. **FAIR VALUE MEASUREMENTS**

The Foundation follows the accounting policy that establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (level 3 measurements). Financial assets valued using level 1 inputs are based on unadjusted quoted market prices within active markets. Financial assets valued using level 2 inputs are based on quoted prices for similar assets in active or inactive markets or quoted prices that are observable for the asset or inputs that are derived from observable market data by correlation or other means. Financial assets valued using level 3 inputs are based on valuation methodology that is unobservable and significant to the fair value measurement.

The hedge funds and limited partnerships, using level 3 inputs, were primarily valued using internal financial statements of the various portfolio funds within the hedge funds and limited partnerships or from redemption values at June 30, 2017. Valuation techniques utilized to determine fair value are applied consistently.

The fair value of assets measured on a recurring basis at June 30, 2017 are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Fair Value</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>June 30, 2017</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limited partnerships</td>
<td>$771,163</td>
<td>$ -</td>
<td>$ -</td>
<td>$771,163</td>
</tr>
<tr>
<td>Stocks</td>
<td>324,679</td>
<td>324,679</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mutual funds</td>
<td>429,320</td>
<td>429,320</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hedge funds</td>
<td>2,699</td>
<td>-</td>
<td>-</td>
<td>2,699</td>
</tr>
<tr>
<td>Totals</td>
<td>$1,527,861</td>
<td>$753,999</td>
<td>-</td>
<td>$773,862</td>
</tr>
</tbody>
</table>

**Fair Value Measurements Using:**
3. FAIR VALUE MEASUREMENTS (Continued)

The following table sets forth a summary of changes in hedge funds and limited partnerships, which are Level 3 assets, for the six-month period ended June 30, 2017:

**Hedge Funds**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balances</td>
<td>$2,690</td>
</tr>
<tr>
<td>Purchases</td>
<td>-</td>
</tr>
<tr>
<td>Sales</td>
<td>-</td>
</tr>
<tr>
<td>Net gains (losses) - realized/unrealized</td>
<td>9</td>
</tr>
<tr>
<td>Ending balances</td>
<td>$2,699</td>
</tr>
</tbody>
</table>

**Limited Partnerships**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balances</td>
<td>$774,078</td>
</tr>
<tr>
<td>Purchases</td>
<td>-</td>
</tr>
<tr>
<td>Sales</td>
<td>(2,915)</td>
</tr>
<tr>
<td>Net gains (losses) - realized/unrealized</td>
<td>-</td>
</tr>
<tr>
<td>Ending balances</td>
<td>$771,163</td>
</tr>
</tbody>
</table>

The following summarizes the investment returns in the Statements of Activities for the six-month period ended June 30:

- Interest and dividends: $17,442
- Realized gains: 24,358
- Unrealized gains: 45,695
- Investment fees: (6,150)

**Investment returns – net gain (loss)**: $81,345

4. GRANTS PAYABLE

During the six-month period ended June 30, 2017, the Foundation expended approximately $1,149,000 for research grants. At June 30, 2017, the Foundation had commitments of $1,697,000 to fund sixteen grants in the next three years. The award amounts of these grants range from approximately $63,000 to $310,000.
4. **GRANTS PAYABLE** (Continued)

Research grants payable at June 30, 2017 are expected to be paid as follows:

<table>
<thead>
<tr>
<th>Year Ending June 30</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>$1,319,477</td>
</tr>
<tr>
<td>2019</td>
<td>378,017</td>
</tr>
<tr>
<td></td>
<td>1,697,494</td>
</tr>
</tbody>
</table>

Less discount at 1.06% to 1.39%

| Less discount at 1.06% to 1.39% | 16,767 |

Research grants payable - net

| Research grants payable - net | $1,680,727 |

In 2017, CRF awarded seven new grants totaling more than $1.32 million for cystinosis research. An additional eight grant agreements were awarded after year-end totaling $1.55 million with the funding of these grants available in cash reserves. The new grants bring CRF closer to better treatments and a cure.

5. **COMMON STOCK**

The par value of each of CCI’s authorized common shares is $0.0001. There are 2,000,000 shares authorized and 1,000,000 shares are issued.

6. **REVENUES AND SUPPORT**

The Foundation receives the majority of its revenues from fundraising events, hosting two major events each year in Orange County, California, the Natalie’s Wish Gala Celebration and the Fore a Cure Golf Tournament. Each of these fundraisers provides the Foundation with the opportunity to educate donors and the public about cystinosis. Funds were raised through corporate sponsorships, donations and auctions. Other fundraising activities are hosted by cystinosis families across the U.S. who enlighten their local communities about cystinosis and the progress of the Foundation funded research. Fundraising revenue was decreased for the costs of direct benefits to donors of $146,966 for the six-month period ended June 30, 2017.

For the six-month period ended June 30, 2017, the Foundation received approximately $860,000 in pledges and cash, from anonymous donors to cover operating and fundraising costs.
7. CONTRIBUTED SERVICES

For the six-month period ended June 30, 2017, contributions include approximately $20,400 of in-kind advertising and printing and $9,500 of in-kind professional services.

A substantial number of unpaid volunteers have made significant contributions to the Foundation’s program services. The value of these contributions is not reflected in these statements since they do not meet the criteria for recognition as contributed services.

8. RELATED PARTY TRANSACTIONS

A Board member’s spouse provided fundraising and administrative consulting services to CRF for the six-month period ended June 30, 2017 of approximately $27,000. At June 30, 2017, approximately $3,000 included in accounts payable were due to related parties.

CRF awards grants to research institutions naming specific researchers. During 2015, CRF awarded a two-year grant for approximately $365,000 to the University of California, San Diego (UCSD) on behalf of a researcher who is also a Board member. At June 30, 2017, approximately $92,000 were included in grants payable to UCSD.

CRF provides loans to CCI. At June 30, 2017, CCI owed CRF $550,000. The loan bears interest at 0.65% and the principal and interest are due in March 2018.

9. INCOME TAXES

CCI’s net operating losses (“NOL”) carryforward of approximately $599,000 will begin to expire in 2036 for federal and state purposes and could be limited for use under IRC Section 382. CCI has recorded a valuation allowance against the entire net deferred tax asset balance because there exists a doubt that it will be able to realize the benefits due to its lack of a history of earnings and due to possible limitations under IRC Section 382.

CCI files its income tax compliance with the IRS and in the states of California and Texas with varying statutes of limitations. CCI’s policy is to recognize interest expense and penalties related to income tax matters as a component of the provision for income taxes. There were no accrued interest and penalties associated with uncertain tax positions as of June 30, 2017.
9. **INCOME TAXES** (Continued)

The net deferred tax asset consists of the following components at June 30, 2017:

Deferred tax assets:
- Net operating loss carry forwards:
  - Federal $200,200
  - State 53,000
  **Total** $253,200
- Valuation allowance (253,200)
- Net deferred tax asset $-

The deferred income tax provision is summarized as follows:

- Federal income tax benefit $100,900
- State income tax benefit 26,700
- **Total income tax benefit** 127,600
- Valuation allowance (127,600)
- Income tax benefit - net $-

CCI believes its income tax filing positions and deductions will be sustained during an audit and do not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded.